Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.0
50.80%
40%
—
-97.05%
40%
—
5 Years
Score4.0
Net Growth50.80%
Net Trend40%
Net Income Consistency—
Rev Growth-97.05%
Rev Trend40%
Revenue Consistency—
Addex Therapeutics Ltd fundamental performance
Between 2020 and 2025, revenue declined from CHF 3M to CHF 29.97K and net income went from -CHF 12M to -CHF 6M. Revenue increased in 2 of those 5 years; net income in 2.
Addex Therapeutics Ltd currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 5.95 | — |
1 Year2025-08-12 | $ 8.00 | -25.62% |
5 Years2021-08-12 | $ 200.00 | -97.02% |
All Time2020-01-29 | $ 290.00 | -97.95% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-01-29 |
|---|---|---|---|---|
| Price | $ 5.95 | $ 8.00 | $ 200.00 | $ 290.00 |
| Return | — | -25.62% | -97.02% | -97.95% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | CHF 86.15K | -CHF 7M | CHF 1M |
| 2025 | CHF 29.97K | -CHF 6M | CHF 1M |
| 2024 | CHF 404.1K | CHF 7M | CHF 3M |
| 2023 | CHF 1M | -CHF 10M | CHF 3M |
| 2022 | CHF 1M | -CHF 20M | CHF 6M |
| 2021 | CHF 2M | -CHF 15M | CHF 20M |
| IPO2020 | CHF 3M | -CHF 12M | CHF 18M |
Explore beyond ADXN
You're looking at Addex Therapeutics Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
